Clinical trial
Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab: A Randomized Controlled Trial
NCT06520397 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab: A Randomized Controlled Trial
- Lead sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- July 15, 2024
- Completion date
- July 31, 2027
- Enrollment
- 214 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.